OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
603087$53.6459

603087.SS

PharmaceuticalsVerified

The company maintains a strong liquidity position, with a current ratio of 6.72, indicating a robust ability to meet short-term obligations. Its cash and equivalents amount to 77.43 million CNY, while its operating cash flow stands at 784.28 million CNY, suggesting a healthy cash-generating business model. The company's price-to-book ratio is 2.76, and its price-to-tangible-book ratio is also 2.76, indicating that the market values the company's equity at a premium relative to its book value. In terms of profitability, the company's return on equity (ROE) is 9.83%, and its return on assets (ROA) is 9.06%, both of which are strong indicators of efficient use of equity and assets. The company's net income of 1.14 billion CNY and operating income of 1.18 billion CNY further underscore its profitability. These metrics suggest that the company is performing well relative to industry standards, although specific industry medians are not provided in the data. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the data. However, the company's total revenue of 4.05 billion CNY indicates a significant market presence. The geographic exposure is not explicitly detailed, but the company's operations are likely centered in China, given the CNY-based financials and the ticker symbol. The company's growth trajectory is positive, with a mean price target of 77.00 CNY from analysts, which is significantly higher than the current market price of 53.64 CNY. This suggests that analysts have a bullish outlook on the company's future performance. The company's revenue history and future outlook are not explicitly detailed, but the strong profitability and liquidity position support a positive growth narrative. The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.0, indicating that it is not leveraged and does not have significant debt obligations. The absence of dilution risks is further supported by the fact that the number of shares outstanding is the same for both basic and diluted shares. Recent events, such as analyst estimates and price targets, indicate a strong investor sentiment towards the company. The mean recommendation from analysts is 1.50, which is a strong buy rating. The company has received one strong-buy and one buy recommendation, with no hold or sell recommendations, further reinforcing the positive outlook.

30-day price · 603087-11.24 (-17.5%)
Low$52.00High$66.57Close$53.05As of28 May, 00:00 UTC
Profile
Company603087.SS
Ticker603087.SS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Classification. The company is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

The company maintains a strong liquidity position, with a current ratio of 6.72, indicating a robust ability to meet short-term obligations. Its cash and equivalents amount to 77.43 million CNY, while its operating cash flow stands at 784.28 million CNY, suggesting a healthy cash-generating business model. The company's price-to-book ratio is 2.76, and its price-to-tangible-book ratio is also 2.76, indicating that the market values the company's equity at a premium relative to its book value. In terms of profitability, the company's return on equity (ROE) is 9.83%, and its return on assets (ROA) is 9.06%, both of which are strong indicators of efficient use of equity and assets. The company's net income of 1.14 billion CNY and operating income of 1.18 billion CNY further underscore its profitability. These metrics suggest that the company is performing well relative to industry standards, although specific industry medians are not provided in the data. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the data. However, the company's total revenue of 4.05 billion CNY indicates a significant market presence. The geographic exposure is not explicitly detailed, but the company's operations are likely centered in China, given the CNY-based financials and the ticker symbol. The company's growth trajectory is positive, with a mean price target of 77.00 CNY from analysts, which is significantly higher than the current market price of 53.64 CNY. This suggests that analysts have a bullish outlook on the company's future performance. The company's revenue history and future outlook are not explicitly detailed, but the strong profitability and liquidity position support a positive growth narrative. The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.0, indicating that it is not leveraged and does not have significant debt obligations. The absence of dilution risks is further supported by the fact that the number of shares outstanding is the same for both basic and diluted shares. Recent events, such as analyst estimates and price targets, indicate a strong investor sentiment towards the company. The mean recommendation from analysts is 1.50, which is a strong buy rating. The company has received one strong-buy and one buy recommendation, with no hold or sell recommendations, further reinforcing the positive outlook.
Key takeaways
  • The company has a strong liquidity position with a current ratio of 6.72 and a healthy operating cash flow of 784.28 million CNY.
  • The company's profitability is robust, with a return on equity of 9.83% and a return on assets of 9.06%.
  • Analysts have a bullish outlook on the company, with a mean price target of 77.00 CNY, significantly higher than the current market price.
  • The company has low liquidity and dilution risks, with no immediate filing-based flags detected.
  • The company is not leveraged, as indicated by a debt-to-equity ratio of 0.0.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$4.05B
Gross profit$3.07B
Operating income$1.18B
Net income$1.14B
R&D
SG&A
D&A
SBC
Operating cash flow$784.3M
CapEx-$926.1M
Free cash flow-$76.6M
Total assets$12.63B
Total liabilities$998.6M
Total equity$11.63B
Cash & equivalents$77.4M
Long-term debt$9.7M
Valuation
Market price$53.64
Market cap$32.04B
Enterprise value$31.97B
P/E28.0
Reported non-GAAP P/E
EV/Revenue7.9
EV/Op income27.0
EV/OCF40.8
P/B2.8
P/Tangible book2.8
Tangible book$11.63B
Net cash$67.8M
Current ratio6.7
Debt/Equity0.0
ROA9.1%
ROE9.8%
Cash conversion69.0%
CapEx/Revenue-22.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
Metric603087Activity
Op margin29.2%2.4% medp25 -91.8% · p75 12.5%top quartile
Net margin28.2%1.2% medp25 -98.4% · p75 10.4%top quartile
Gross margin75.7%45.6% medp25 29.8% · p75 66.7%top quartile
CapEx / revenue-22.9%-5.2% medp25 -15.8% · p75 -1.7%bottom quartile
Debt / equity0.0%9.3% medp25 0.1% · p75 43.8%bottom quartile
Observations
IR observations
Mean price target77.00 CNY
Median price target77.00 CNY
High price target77.00 CNY
Low price target77.00 CNY
Mean recommendation1.50 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate2.40 CNY
Last actual EPS1.93 CNY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 21:40 UTC#35a8ac60
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 00:55 UTCJob: da6fd017